Caligan Partners LP acquired 1,553,262 shares of Exelixis Inc (EXEL) at a price of $43.12 per share, totaling $66.98 million. Following this transaction, Caligan Partners holds the same number of shares in the company.
Exelixis, a biotechnology firm based in Alameda, California, focuses on developing new medicines for difficult-to-treat cancers. The company has a market capitalization of $11.9 billion and reported a trailing P/E ratio of 17.49 and an EPS of 2.38. Exelixis has produced four marketed pharmaceutical products, including cabozantinib, which is approved for various cancer treatments. The company is also advancing its product pipeline, with its lead investigational asset being zanzalintinib.
This insider purchase reflects confidence in the company’s future prospects, as executives typically have access to non-public information. However, evaluating insider transactions requires caution, as motivations can vary widely.
Insider transactions are reported to the SEC, offering transparency into executives' views on their stock. Investors are encouraged to consider patterns of insider activity across multiple individuals and time periods alongside other fundamental and technical factors. Exelixis is scheduled to report earnings on January 12, 2026, with an estimated EPS of $0.68 and revenue of $621.2 million.